Search Results - Hyeyeong Kim

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Do hospital data breaches affect health information technology investment? by Jinhyung Lee, Hyeyeong Kim, Sung J Choi

    Published in Digital Health (2024-01-01)
    Get full text
    Article


  2. 2

    Development and pilot study of “Smart Cancer Care”: a platform for managing side effects of chemotherapy by Cheolkyung Sin, Hyeyeong Kim, Hyeon-Su Im, Minsu Ock, Su-Jin Koh

    Published in BMC Health Services Research (2023-08-01)
    Get full text
    Article


  3. 3

    Effectiveness of self-reported management program of cancer patients by Cheolkyung Sin, Dong Yeop Lee, Hyeyeong Kim, Hyeon-Su Im, Su-Jin Koh, Dong Yoon Kang

    Published in Digital Health (2024-07-01)
    Get full text
    Article


  4. 4

    Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma by Jaekyung Cheon, Hyeyeong Kim, Han Sang Kim, Chang Gon Kim, Ilhwan Kim, Beodeul Kang, Chan Kim, Sanghoon Jung, Yeonjung Ha, Hong Jae Chon

    Published in Therapeutic Advances in Medical Oncology (2023-01-01)
    Get full text
    Article


  5. 5

    Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment by Young Eun Chon, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do young Kim, Seong Gyu Hwang, Hong Jae Chon, Beom Kyung Kim

    Published in Cancer Medicine (2023-02-01)
    Get full text
    Article


  6. 6

    Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma by Young Shin Song, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Ho Yeong Lim, Vincent E. Gaillard, Chan Kim, Hong Jae Chon

    Published in Liver Cancer (2023-05-01)
    Get full text
    Article


  7. 7

    High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma by Hannah Yang, Beodeul Kang, Yeonjung Ha, Sung Hwan Lee, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Gwangil Kim, Sanghoon Jung, Sun Young Rha, Vincent E. Gaillard, Jaekyung Cheon, Chan Kim, Hong Jae Chon

    Published in JHEP Reports (2023-04-01)
    Get full text
    Article


  8. 8

    Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study by Jung Sun Kim, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Jung Yong Hong, Ho Yeong Lim, Han Sang Kim, Chang Gon Kim, Sanghoon Jung, Chansik An, Chan Kim, Hong Jae Chon

    Published in Cancer Medicine (2025-06-01)
    Get full text
    Article


  9. 9

    Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22... by Sung Hee Lim, Keun-Wook Lee, Jae-Joon Kim, Hyeon-Su Im, In-Ho Kim, Hye Sook Han, Dong-Hoe Koo, Jang Ho Cho, Chi Hoon Maeng, Min-Young Lee, Hyo Jin Lee, Jwa Hoon Kim, Sang Gon Park, Joo Young Jung, Seong-Hoon Shin, Ki Hyang Kim, Hyeyeong Kim, So Yeon Oh, Minsu Kang, Minkyu Jung, Sun Young Rha

    Published in BMC Cancer (2024-02-01)
    Get full text
    Article


  10. 10

    Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries by Choong-kun Lee, Changhoon Yoo, Jung Yong Hong, Se Jun Park, Jin Won Kim, David Wai Meng Tai, Hyeyeong Kim, Krittiya Korphaisarn, Suebpong Tanasanvimon, San-Chi Chen, Ju Won Kim, Ilhwan Kim, Moonho Kim, Joan Choo, Sang-Bo Oh, Ching-Tso Chen, Woo Kyun Bae, Hongsik Kim, Seok Jae Huh, Chia-Jui Yen, Sejung Park, Dong Ki Lee, Landon Long Chan, Beodeul Kang, Minsu Kang, Raghav Sundar, Hye Jin Choi, Stephen Lam Chan, Hong Jae Chon, Myung-Ah Lee

    Published in Liver Cancer (2024-08-01)
    Get full text
    Article


Search Tools: